Don’t Let Depression Keep You In The Dark.
At PsychDFW, we pride ourselves on taking a multifaceted approach to heal your mind and restoring your mental and psychological wellness.
Spravato Therapy in Dallas
Covered By Insurance
Spravato therapy, also known as Esketamine for Treatment-Resistant Depression, is a relatively new treatment for depression that has been approved by the US Food and Drug Administration (FDA) in 2019. This treatment has shown promise in treating individuals who have not responded to other depression treatments, such as antidepressant medications and psychotherapy.
Spravato praised as effective treatment for depression
Why Choose PsychDFW for Spravato Therapy.
Depression is a highly challenging and sensitive condition among adults as well as children. We, at PsychDFW, help individuals suffering from this condition and treat them to lead a healthy, happy life. Our professional depression psychiatrist in Fort Worth, Dr Raju Indukuri, with his 30 years of experience and expertise, tackles depression disorders and provides affordable mental healthcare to everyone in need. Call us now to make an appointment or stop by in person at our medical psychiatry office.
What We Treat
At PsychDFW, we pride ourselves on taking a multifaceted approach to heal your mind and restoring your mental and psychological wellness. Our focus is to help individuals become aware of their inner strength and heal their minds. We achieve this by giving you a neutral safe space where you can feel comfortable. We listen to your concerns and tailor a treatment plan suited to your psychological needs
Learn More About Spravato Therapy
Spravato therapy, also known as esketamine therapy, is a relatively new treatment option for individuals with treatment-resistant depression. Approved by the U.S. Food and Drug Administration (FDA) in 2019, Spravato is a nasal spray that contains esketamine, a variation of ketamine.
Spravato therapy is only available with a prescription and must be administered under the supervision of a healthcare professional in a healthcare setting. The first step in receiving Spravato therapy is to be evaluated by a healthcare professional to determine if it is an appropriate treatment option. If it is deemed appropriate, the healthcare professional will administer the nasal spray and monitor the individual for any potential side effects. Ketamine has been used for many years as an anesthetic, but it has also shown promise in treating depression. However, due to its potential for abuse and addiction, it is classified as a Schedule III controlled substance by the Drug Enforcement Administration (DEA). Esketamine, on the other hand, has been developed as a form of ketamine that can be used safely and effectively in a clinical setting.
Spravato therapy is designed for individuals who have not responded to other treatments for depression, including antidepressant medications and psychotherapy. It is not a first-line treatment option and is reserved for individuals who have severe, treatment-resistant depression.
Spravato therapy is only available with a prescription and must be administered under the supervision of a healthcare professional in a healthcare setting. The first step in receiving Spravato therapy is to be evaluated by a healthcare professional to determine if it is an appropriate treatment option. If it is deemed appropriate, the healthcare professional will administer the nasal spray and monitor the individual for any potential side effects. Ketamine has been used for many years as an anesthetic, but it has also shown promise in treating depression. However, due to its potential for abuse and addiction, it is classified as a Schedule III controlled substance by the Drug Enforcement Administration (DEA). Esketamine, on the other hand, has been developed as a form of ketamine that can be used safely and effectively in a clinical setting.
Spravato therapy is designed for individuals who have not responded to other treatments for depression, including antidepressant medications and psychotherapy. It is not a first-line treatment option and is reserved for individuals who have severe, treatment-resistant depression.
Spravato is administered through a nasal spray that is self-administered under the supervision of a healthcare provider. The first two doses are usually given one week apart, followed by maintenance doses once every two weeks or once a month, depending on the individual’s response to treatment.
The exact mechanism of action of Spravato is not fully understood, but it is thought to work by increasing the availability of certain neurotransmitters in the brain, including glutamate and serotonin. These neurotransmitters are involved in mood regulation, and increasing their availability can improve symptoms of depression.
The exact mechanism of action of Spravato is not fully understood, but it is thought to work by increasing the availability of certain neurotransmitters in the brain, including glutamate and serotonin. These neurotransmitters are involved in mood regulation, and increasing their availability can improve symptoms of depression.
Spravato is a nasal spray that contains esketamine, which is a variant of the anesthetic ketamine. Ketamine is a dissociative anesthetic that has been used for decades in medical settings. However, its use has been limited due to its potential for abuse and its hallucinogenic effects. Esketamine, on the other hand, has been found to have fewer side effects and less potential for abuse.
The mechanism of action of Spravato is not fully understood, but it is believed to work by restoring the balance of certain chemicals in the brain, such as glutamate, which play a role in mood regulation. Spravato is thought to act on the N-methyl-D-aspartate (NMDA) receptor, which is involved in the release of glutamate. By acting on this receptor, Spravato is thought to increase the release of glutamate, which in turn stimulates the growth of new neural connections in the brain, leading to improved mood and decreased depression symptoms.
The mechanism of action of Spravato is not fully understood, but it is believed to work by restoring the balance of certain chemicals in the brain, such as glutamate, which play a role in mood regulation. Spravato is thought to act on the N-methyl-D-aspartate (NMDA) receptor, which is involved in the release of glutamate. By acting on this receptor, Spravato is thought to increase the release of glutamate, which in turn stimulates the growth of new neural connections in the brain, leading to improved mood and decreased depression symptoms.
Spravato therapy has several benefits for individuals with treatment-resistant depression. First, it has been shown to be effective in reducing symptoms of depression, including feelings of sadness, hopelessness, and worthlessness. Second, it has a rapid onset of action, with many individuals experiencing improvement in their symptoms within hours or days of their first dose. Third, it can be an alternative treatment option for individuals who have not responded to other treatments for depression, including antidepressant medications and psychotherapy.
Clinical trials have shown that Spravato therapy can be effective in reducing depression symptoms in individuals who have not responded to other depression treatments. One study found that individuals who received Spravato therapy had a significant reduction in depression symptoms compared to those who received a placebo nasal spray. Additionally, a significant proportion of individuals who received Spravato therapy had a remission of their depression symptoms.
Side Effects:
Like any medication, Spravato therapy can have potential side effects. The most common side effects reported in clinical trials include dizziness, nausea, dissociation, and headache. These side effects are usually mild and temporary, and they typically subside within a few hours after the treatment. However, there is a risk of more serious side effects, such as changes in blood pressure or heart rate, which can be monitored by a healthcare professional during the treatment.
Like all medications, Spravato therapy has potential side effects and risks. Some of the most common side effects reported with Spravato include:
- Dizziness Disorientation
- Sedation
- Headache
- Nausea
- Vomiting
- Increased blood
- pressure
- Feeling disconnected from reality
- Blurred vision
Some individuals may also experience more serious side effects, such as hallucinations, delusions, and suicidal thoughts. Because of these risks, Spravato is only administered in a healthcare setting and is closely monitored by a healthcare provider.
In addition to these potential side effects, there is also concern about the long-term effects of Spravato therapy, as it is a relatively new treatment option. However, early studies have shown that it is generally safe and well-tolerated when used as directed.
In conclusion, Spravato therapy is a new treatment option for depression that has shown promise in individuals who have not responded to other depression treatments. While it is not without potential side effects, the benefits of this treatment may outweigh the risks for some individuals. It is important to speak with a healthcare professional to determine if Spravato therapy is an appropriate treatment option for you.
If you have treatment-resistant depression and have not responded to other treatments, Spravato therapy may be a viable treatment option for you.
However, it is important to discuss your options with your healthcare provider to determine if it is right for you. Your healthcare provider can help you weigh the benefits and risks of the treatment and determine if it is the best course of action for your individual needs.
However, it is important to discuss your options with your healthcare provider to determine if it is right for you. Your healthcare provider can help you weigh the benefits and risks of the treatment and determine if it is the best course of action for your individual needs.
Insurance We Commonly Accept
Our office accepts most major PPO insurance plans. We accept Aetna, BCBS, Cigna, Tricare, UMR, and United. If you have any questions about your plan, please call our office at (817) 222-9907. If we are not on your plan, we will provide the information you need to file your claim for reimbursement.
